85926-99-4

Basic information

• Product Name: indoline-4-ol
• Synonyms: indoline-4-ol;2,3-Dihydro-1H-indol-4-ol;Einecs 288-871-5;4-Hydroxyindoline;indolin-4-ol;1H-INDOL-4-OL,2,3-DIHYDRO-
• CAS NO: 85926-99-4
• Molecular Formula: C₈H₉NO
• Molecular Weight: 135.16316
• EINECS: 288-871-5
• Mol File: 85926-99-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 139-140℃
• Boiling Point: 281℃
• Flash Point: 160℃
• Appearance: /
• Density: 1.196
• Vapor Pressure: 0.00216mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: indoline-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: indoline-4-ol(85926-99-4)
• EPA Substance Registry System: indoline-4-ol(85926-99-4)

Safety Data

• Hazardous Substances Data: 85926-99-4(Hazardous Substances Data)

Usage

General Description

Indoline-4-ol, also known as Oxindole, is a chemical compound belonging to the group of indolines, which are nitrogenous heterocyclic compounds. It is used greatly in the process of producing medication, primarily because of its ability to act as an inhibitor for a variety of enzymes. Consequently, it has potential anti-cancer properties and it can also influence the immune system. It exists in various modified forms which can have different biomedical applications, enhancing its versatility in medical and chemical research. Its formulation is usually in a liquid state and it requires careful handling due to its moderately toxic characteristics.

InChI:InChI=1/C8H9NO/c10-8-3-1-2-7-6(8)4-5-9-7/h1-3,9-10H,4-5H2

Upstream product

• 52537-01-6 4-aminoindoline 
• 118742-89-5 2-(2,6-diaminophenyl)ethanol 
• 2380-94-1 1H-indol-4-ol 
• 77759-08-1 2-(2,6-dinitrophenyl)ethanol 
• 606-20-2 2,6-dinitrotoluene 
• 496-15-1 1-indoline 

Downstream Products

• 737816-53-4 4-acetoxy-1-acetylindoline 
• 1452925-60-8 C₁₅H₁₅NO₃S 
• 1452925-64-2 3-(7-bromo-4-hydroxy-1-tosylindolin-5-yl)propanoic acid 
• 1452925-73-3 (2'S,3aR,6R,9S)-9-acetyl-7-bromo-1-tosyl-2,3-dihydro-1H,3'H-spiro[3a,6-ethanoindole-5,2'-furan]-4,5'(4'H,6H)-dione 
• 1452925-74-4 (2'S,3aR,6R,9R)-7-bromo-9-phenyl-1-tosyl-2,3-dihydro-1H,3'H-spiro[3a,6-ethanoindole-5,2'-furan]-4,5'(4'H,6H)-dione 
• 1452925-61-9 C₂₂H₂₇NO₅S 
• 1452925-62-0 C₂₀H₂₃NO₅S 
• 1452925-63-1 C₂₀H₂₂BrNO₅S 
• 2380-94-1 1H-indol-4-ol 

Relevant articles and documents

550 nm excited rhodamine dye and preparation method thereof

The invention provides 550 nm excited rhodamine fluorescent dye and a preparation method thereof. The structural formula of the rhodamine fluorescent dye is as shown in (1), and through structural modification of a rigid five-membered ring, the absorption and emission wavelengths of the rhodamine fluorescent dye generate a certain red shift (about 50 nm) compared with rhodamine 110. Meanwhile, rawmaterials used in the invention are cheap and easily available, the operation is simple, requirements on experiments are low, and the obtained novel rhodamine fluorescent dye has high light stabilityand high quantum yield (up to 0.93 in ethanol), and can be widely applied to the field of biological fluorescence imaging.

INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF

The invention provides indole and indoline derivatives and slats thereof, compositions comprising them and uses thereof for the treatment of diseases and disorders.

S1P RECEPTORS MODULATORS

The invention relates to novel compounds that have S1P receptor modulating activity and, preferably, apoptotic activity and/or anti proliferative activity against cancer cells and other cell types. Further, the invention relates to a pharmaceutical comprising at least one compound of the invention for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression, for example, cancer. A further aspect of the invention relates to the use of a pharmaceutical comprising at least one compound of the invention for the manufacture of a medicament for the treatment of diseases and/or conditions caused by or associated with inappropriate S1P receptor modulating activity or expression such as cancer.